azomycin has been researched along with Aura in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biagini, G; Gualtieri, F; Longo, D; Marinelli, C; Meletti, S; Nichelli, PF; Pugnaghi, M | 1 |
| Kogelnik, HD | 1 |
1 trial(s) available for azomycin and Aura
| Article | Year |
|---|---|
Clinical experience with misonidazole: high dose fractions versus daily low doses.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Epilepsy; Female; Hearing Loss; Humans; Male; Middle Aged; Misonidazole; Neurocognitive Disorders; Nitroimidazoles; Peripheral Nervous System Diseases | 1980 |
1 other study(ies) available for azomycin and Aura
| Article | Year |
|---|---|
Hypoxia markers are expressed in interneurons exposed to recurrent seizures.
Topics: Animals; Anticonvulsants; Biomarkers; Cell Hypoxia; Cerebral Cortex; Convulsants; Diazepam; Disease Progression; Drug Resistance; Epilepsy; HMGB1 Protein; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Interneurons; Male; Nerve Tissue Proteins; Neuropeptide Y; Nitroimidazoles; Parvalbumins; Pilocarpine; Rats; Rats, Sprague-Dawley; Recurrence; Seizures; Status Epilepticus | 2013 |